Minimizing Systemic Inflammation During Cardiopulmonary Bypass in the Pediatric Population

Artificial Organs

Volumn 38, Issue 1, 2014, Pages 11-18

  Durandy, Yves ^a  

^a UNIVERSITÉ D'ARTOIS   (France)

Author keywords

Cardiopulmonary bypass; Inflammation; Pediatrics; Systemic inflammatory response syndrome

Indexed keywords

CARDIOVASCULAR SURGERY; PATHOLOGY;

BLOOD CONTACT; BYPASS CIRCUITS; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; CYTOKINES; INFLAMMATORY RESPONSE; ISCHAEMIA-REPERFUSION; PEDIATRIC POPULATION; SYSTEMIC INFLAMMATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES;

PEDIATRICS;

ACETYLSALICYLIC ACID; ANTIOXIDANT; ANTITHROMBIN III; APROTININ; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPEXAMINE; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; KETAMINE; PEXELIZUMAB; PHOSPHODIESTERASE INHIBITOR; SCAVENGER;

BLOOD AUTOTRANSFUSION; CARDIOPULMONARY BYPASS; CHILDHOOD DISEASE; CORTICOSTEROID THERAPY; ENDOTOXEMIA; HEMOFILTRATION; HUMAN; IMMUNOTHERAPY; LEUKOCYTE; NONHUMAN; OFF PUMP SURGERY; PEDIATRIC SURGERY; PERFUSION; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; PULSATILE FLOW; REPERFUSION; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TEMPERATURE; ULTRAFILTRATION;

CARDIOPULMONARY BYPASS; INFLAMMATION; PEDIATRICS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANTI-INFLAMMATORY AGENTS; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CHILD; HEMOFILTRATION; HUMANS; INFLAMMATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84891902764     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12195     Document Type: Review

References (94)

1. Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg 1997;84:920-935.
2. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997;112:676-692.
3. Warren OJ, Smith AJ, Alexiou C, etal. The inflammatory response to cardiopulmonary bypass: part 1-mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009;23:223-231.
4. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002;97:215-252.
5. Zhang S, Wang S, Yao S. Evidence for development of capillary leak syndrome associated with cardiopulmonary bypass in pediatric patients with the homozygous C4A null phenotype. Anesthesiology 2004;100:1387-1393.
6. Ryan T, Balding J, McGovern EM, etal. Lactic acidosis after cardiac surgery is associated with polymorphisms in tumor necrosis factor and interleukin 10 genes. Ann Thorac Surg 2002;73:1905-1909.
7. Schroeder S, Börger N, Wrigge H, etal. A tumor necrosis factor gene polymorphism influences the inflammatory response after cardiac operation. Ann Thorac Surg 2003;75:534-537.
8. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999;27:1262-1264.
9. Hövels-Gürich HH, Schumacher K, Vazquez-Jimenez JF, etal. Cytokine balance in infants undergoing cardiac operation. Ann Thorac Surg 2002;73:601-608.
10. Qing M, Vazquez-Jimenez JF, Klosterhalfen B, etal. Influence of temperature during cardiopulmonary bypass on leukocyte activation, cytokine balance, and post-operative organ damage. Shock 2001;15:372-377.
11. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125-1128.
12. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003;75:S715-720.
13. Asimakopoulos G, Gourlay T. A review of anti-inflammatory strategies in cardiac surgery. Perfusion 2003;18(Suppl. 1):7-12.
14. Faraoni D. Management of perioperative systemic inflammation during cardiopulmonary bypass: we need a multimodal approach. Recent Pat Cardiovasc Drug Discov 2012;7:163-164.
15. Gessler P, Hohl V, Carrel T, etal. Administration of steroids in pediatric cardiac surgery:impact on clinical outcome and systemic inflammatory response. Pediatr Cardiol 2005;26:595-600.
16. Dieleman JM, Nierich AP, Rosseel PM, etal. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA 2012;308:1761-1767.
17. Varan B, Tokel K, Mercan S, Dönmez A, Aslamaci S. Systemic inflammatory response related to cardiopulmonary bypass and its modification by methyl prednisolone: high dose versus low dose. Pediatr Cardiol 2002;23:437-441.
18. Nebelsiek T, Beiras-Fernandez A, Kilger E, Möhnle P, Weis F. Routine use of corticosteroids to prevent inflammation response in cardiac surgery. Recent Pat Cardiovasc Drug Discov 2012;7:170-174.
19. Morariu AM, Loef BG, Aarts LP, etal. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest 2005;128:2677-2687.
20. Graham EM, Atz AM, Butts RJ, etal. Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg 2011;142:1523-1529.
21. Keski-Nisula J, Pesonen E, Olkkola KT, etal. Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome. Ann Thorac Surg 2013;95:2126-2132.
22. Amand T, Pincemail J, Blaffart F, Larbuisson R, Limet R, Defraigne JO. Levels of inflammatory markers in the blood processed by autotransfusion devices during cardiac surgery associated with cardiopulmonary bypass circuit. Perfusion 2002;17:117-123.
23. Damgaard S, Nielsen CH, Andersen LW, Bendtzen K, Tvede M, Steinbrüchel DA. Cell saver for on-pump coronary operations reduces systemic inflammatory markers: a randomized trial. Ann Thorac Surg 2010;89:1511-1517.
24. Svenmarker S, Engström KG. The inflammatory response to recycled pericardial suction blood and the influence of cell-saving. Scand Cardiovasc J 2003;37:158-164.
25. Sandoval S, Alrawi S, Samee M, etal. A cytokine analysis of the effect of cell saver on blood in coronary bypass surgery. Heart Surg Forum 2001;4:113-117, discussion 117-9.
26. Takayama H, Soltow LO, Aldea GS. Differential expression in markers for thrombin, platelet activation, and inflammation in cell saver versus systemic blood in patients undergoing on-pump coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2007;21:519-523.
27. Kuratani N, Bunsangjaroen P, Srimueang T, Masaki E, Suzuki T, Katogi T. Modified versus conventional ultrafiltration in pediatric cardiac surgery: a meta-analysis of randomized controlled trials comparing clinical outcome parameters. J Thorac Cardiovasc Surg 2011;142:861-867.
28. Bando K, Turrentine MW, Vijay P, etal. Effect of modified ultrafiltration in high-risk patients undergoing operations for congenital heart disease. Ann Thorac Surg 1998;66:821-827.
29. Keenan HT, Thiagarajan R, Stephens KE, Williams G, Ramamoorthy C, Lupinetti FM. Pulmonary function after modified venovenous ultrafiltration in infants: a prospective, randomized trial. J Thorac Cardiovasc Surg 2000;119:501-505.
30. Mahmoud AB, Burhani MS, Hannef AA, Jamjoom AA, Al-Githmi IS, Baslaim GM. Effect of modified ultrafiltration on pulmonary function after cardiopulmonary bypass. Chest 2005;128:3447-3453.
31. Hennein HA, Kiziltepe U, Barst S, etal. Venovenous modified ultrafiltration after cardiopulmonary bypass in children: a prospective randomized study. J Thorac Cardiovasc Surg 1999;117:496-505.
32. Chew MS. Does modified ultrafiltration reduce the systemic inflammatory response to cardiac surgery with cardiopulmonary bypass? Perfusion 2004;19(Suppl. 1):S57-60.
33. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 2002;21:232-244.
34. Gott VL, Whiffen JD, Dutton RC. Heparin bonding on colloidal graphite surfaces. Science 1963;142:1297-1298.
35. Dowling RD, Brown ME, Whittington RO Jr, Quinlan JJ, Armitage JM. Clinical cardiopulmonary bypass without systemic anticoagulation. Ann Thorac Surg 1993;56:1176-1177.
36. Videm V, Svennevig JL, Fosse E, Semb G, Osterud A, Mollnes TE. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992;103:806-813.
37. Mahmood S, Bilal H, Zaman M, Tang A. Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit? Interact Cardiovasc Thorac Surg 2012;14:406-414.
38. Senay S, Toraman F, Gunaydin S, Kilercik M, Karabulut H, Alhan C. The impact of allogenic red cell transfusion and coated bypass circuit on the inflammatory response during cardiopulmonary bypass: a randomized study. Interact Cardiovasc Thorac Surg 2009;8:93-99.
39. Baufreton C, Intrator L, Jansen PG, etal. Inflammatory response to cardiopulmonary bypass using roller or centrifugal pumps. Ann Thorac Surg 1999;67:972-977.
40. Hickey E, Karamlou T, You J, Ungerleider RM. Effects of circuit miniaturization in reducing inflammatory response to infant cardiopulmonary bypass by elimination of allogeneic blood products. Ann Thorac Surg 2006;81:S2367-2372.
41. Bical OM, Fromes Y, Gaillard D, etal. Comparison of the inflammatory response between miniaturized and standard CPB circuits in aortic valve surgery. Eur J Cardiothorac Surg 2006;29:699-702.
42. Brown Mahoney C, Donnelly JE. Impact of closed versus open venous reservoirs on patient outcomes in isolated coronary artery bypass graft surgery. Perfusion 2000;15:467-472.
43. Fromes Y, Gaillard D, Ponzio O, etal. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur J Cardiothorac Surg 2002;22:527-533.
44. Schmidt H, Bendtzen K, Mortensen PE. The inflammatory cytokine response after autotransfusion of shed mediastinal blood. Acta Anaesthesiol Scand 1998;42:558-564.
45. Tuinman PR, Vlaar AP, Cornet AD, etal. Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study. Crit Care 2011;15:R59.
46. Elliott MJ, Finn AH. Interaction between neutrophils and endothelium. Ann Thorac Surg 1993;56:1503-1508.
47. Ratliff NB, Young WG Jr, Hackel DB, Mikat E, Wilson JW. Pulmonary injury secondary to extracorporeal circulation. An ultrastructural study. J Thorac Cardiovasc Surg 1973;65:425-432.
48. Wilson IC, Gardner TJ, DiNatale JM, Gillinov AM, Curtis WE, Cameron DE. Temporary leukocyte depletion reduces ventricular dysfunction during prolonged postischemic reperfusion. J Thorac Cardiovasc Surg 1993;106:805-810.
49. Cameron D. Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. J Cardiovasc Pharmacol 1996;27(Suppl. 1):S1-5.
50. Englander R, Cardarelli MG. Efficacy of leukocyte filters in the bypass circuit for infants undergoing cardiac operations. Ann Thorac Surg 1995;60(6 Suppl.):S533-535.
51. Matheis G, Scholz M, Simon A, Dzemali O, Moritz A. Leukocyte filtration in cardiac surgery: a review. Perfusion 2001;16:361-370.
52. Greilich PE, Brouse CF, Whitten CW, Chi L, Dimaio JM, Jessen ME. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 2003;126:1498-1503.
53. Tassani P, Augustin N, Barankay A, Braun SL, Zaccaria F, Richter JA. High-dose aprotinin modulates the balance between proinflammatory and antiinflammatory responses during coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2000;14:682-686.
54. Later AF, Sitniakowsky LS, van Hilten JA, etal. Antifibrinolytics attenuate inflammatory gene expression after cardiac surgery. J Thorac Cardiovasc Surg 2013;145:1611-1616.
55. Maillet F, Kazatchkine MD, Glotz D, Fischer E, Rowe M. Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. Mol Immunol 1983;20:1401-1404.
56. Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP. Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992;148:3210-3215.
57. Yan AT, Goodman SG. Low-molecular-weight heparins in ischemic heart disease. Curr Opin Cardiol 2004;19:309-316.
58. Becker RC, Mahaffey KW, Yang H, etal. Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. J Thromb Thrombolysis 2011;31:146-153.
59. Pevni D, Frolkis I, Shapira I, etal. Heparin added to cardioplegic solution inhibits tumor necrosis factor-alpha production and attenuates myocardial ischemic-reperfusion injury. Chest 2005;128:1805-1811.
60. Barry WH, Kennedy TP. Heparins with reduced anti-coagulant activity reduce myocardial reperfusion injury. Recent Pat Cardiovasc Drug Discov 2011;6:148-157.
61. Levy JH. Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas. Hematol Oncol Clin North Am 2007;21:89-101.
62. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994;58:799-804.
63. Wu R, Lamontagne D, de Champlain J. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 2002;105:387-392.
64. Diehl P, Olivier C, Bode C, Moser M. Editorial comment: reduction of oxidative stress: a new indication for acetylsalicylic acid in coronary artery bypass surgery. Eur J Cardiothorac Surg 2013;43:1163-1164.
65. Berg K, Langaas M, Ericsson M, etal. Acetylsalicylic acid treatment until surgery reduces oxidative stress and inflammation in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg 2013;43:1154-1163.
66. Le Deist F, Menasché P, Kucharski C, Bel A, Piwnica A, Bloch G. Hypothermia during cardiopulmonary bypass delays but does not prevent neutrophil-endothelial cell adhesion. A clinical study. Circulation 1995;92(9 Suppl.):II354-358.
67. Speziale G, Ferroni P, Ruvolo G, etal. Effect of normothermic versus hypothermic cardiopulmonary bypass on cytokine production and platelet function. J Cardiovasc Surg (Torino) 2000;41:819-827.
68. Eggum R, Ueland T, Mollnes TE, etal. Effect of perfusion temperature on the inflammatory response during pediatric cardiac surgery. Ann Thorac Surg 2008;85:611-617.
69. Stocker CF, Shekerdemian LS, Horton SB, etal. The influence of bypass temperature on the systemic inflammatory response and organ injury after pediatric open surgery: a randomized trial. J Thorac Cardiovasc Surg 2011;142:174-180.
70. Gerçekoglu H, Tarim O, Agar I, etal. Effects of hypothermia on blood endogenous endotoxin levels during cardiopulmonary bypass. J Card Surg 1997;12:223-227.
71. Asimakopoulos G. Systemic inflammation and cardiac surgery: an update. Perfusion 2001;16:353-360.
72. Tárnok A, Hambsch J, Emmrich F, etal. Complement activation, cytokines, and adhesion molecules in children undergoing cardiac surgery with or without cardiopulmonary bypass. Pediatr Cardiol 1999;20:113-125.
73. Watarida S, Mori A, Onoe M, etal. A clinical study on the effects of pulsatile cardiopulmonary bypass on the blood endotoxin levels. J Thorac Cardiovasc Surg 1994;108:620-625.
74. Neuhof C, Wendling J, Dapper F, etal. Endotoxemia and cytokine generation in cardiac surgery in relation to flow mode and duration of cardiopulmonary bypass. Shock 2001;16(Suppl. 1):39-43.
75. Hoffman TM, Wernovsky G, Atz AM, etal. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics. Am Heart J 2002;143:15-21.
76. Craciun EM, Altfelder F, Kuss N, Poeschl J, Ruef P. Anti-inflammatory effects of selected drugs on activated neonatal and adult neutrophils. Scand J Clin Lab Invest 2013;73:407-413.
77. Koike T, NadeenQutab M, Tsuchida M, Takekubo M, Saito M, Hayashi J. Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect. Pulm Pharmacol Ther 2008;21:166-171.
78. Boldt J, Brosch C, Suttner S, Piper SN, Lehmann A, Werling C. Prophylactic use of the phospodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function. Intensive Care Med 2002;28:1462-1469.
79. Berendes E, Möllhoff T, Van Aken H, etal. Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Anesth Analg 1997;84:950-957.
80. Bach F, Grundmann U, Bauer M, etal. Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia. Acta Anaesthesiol Scand 2002;46:1227-1235.
81. Pyles LA, Fortney JE, Kudlak JJ, Gustafson RA, Einzig S. Plasma antioxidant depletion after cardiopulmonary bypass in operations for congenital heart disease. J Thorac Cardiovasc Surg 1995;110:165-171.
82. Sisto T, Paajanen H, Metsä-Ketelä T, Harmoinen A, Nordback I, Tarkka M. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann Thorac Surg 1995;59:1519-1523.
83. Ren Z, Ding W, Su Z, etal. Mechanisms of brain injury with deep hypothermic circulatory arrest and protective effects of coenzyme Q10. J Thorac Cardiovasc Surg 1994;108:126-133.
84. Welters ID, Feurer MK, Preiss V, etal. Continuous S-(+)-ketamine administration during elective coronary artery bypass graft surgery attenuates pro-inflammatory cytokine response during and after cardiopulmonary bypass. Br J Anaesth 2011;106:172-179.
85. Dale O, Somogyi AA, Li Y, Sullivan T, Shavit Y. Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis. Anesth Analg 2012;115:934-943.
86. Brull DJ, Sanders J, Rumley A, Lowe GD, Humphries SE, Montgomery HE. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart 2002;87:252-255.
87. Dagenais GR, Yusuf S, Bourassa MG, etal. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104:522-526.
88. Kambam J, Meszaros R, Merrill W, Stewart J, Smith BE, Bender H. Prophylactic administration of histamine1 and histamine2 receptor blockers in the prevention of protamine-related haemodynamic effects. Can J Anaesth 1990;37:420-422.
89. Parsons RS, Mohandas K. The effect of histamine-receptor blockade on the hemodynamic responses to protamine. J Cardiothorac Anesth 1989;3:37-43.
90. Allan CK, Newburger JW, McGrath E, etal. The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg 2010;111:1244-1251.
91. Lequier LL, Nikaidoh H, Leonard SR, etal. Preoperative and postoperative endotoxemia in children with congenital heart disease. Chest 2000;117:1706-1712.
92. Kats S, Schönberger JP, Brands R, Seinen W, van Oeveren W. Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update. Eur J Cardiothorac Surg 2011;39:451-458.
93. Allen M, Sundararajan S, Pathan N, Burmester M, Macrae D. Anti-inflammatory modalities: their current use in pediatric cardiac surgery in the United Kingdom and Ireland. Pediatr Crit Care Med 2009;10:341-345.
94. Hövels-Gürich HH, Vazquez-Jimenez JF, Silvestri A, etal. Production of proinflammatory cytokines and myocardial dysfunction after arterial switch operation in neonates with transposition of the great arteries. J Thorac Cardiovasc Surg 2002;124:811-820.